Chimeric Therapeutics Ltd
ASX:CHM

Watchlist Manager
Chimeric Therapeutics Ltd Logo
Chimeric Therapeutics Ltd
ASX:CHM
Watchlist
Price: 0.005 AUD Market Closed
Market Cap: 9.1m AUD

Intrinsic Value

CHM's intrinsic value estimate is unreliable because it is based only on its DCF value and doesn't use a relative valuation using multiples.

The intrinsic value of one CHM stock under the Base Case scenario is 0.01 AUD. Compared to the current market price of 0.005 AUD, Chimeric Therapeutics Ltd is Undervalued by 51%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

CHM Intrinsic Value
0.01 AUD
Undervaluation 51%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Chimeric Therapeutics Ltd

Valuation History Unavailable

Historical valuation for CHM cannot be conducted due to limitations such as insufficient data or other constraints.

Valuation In Progress...
Valuation In Progress...
0%

Fundamental Analysis

Company Overview
Loading...
Management
Loading...
Contacts
Loading...
AI Assistant
AI Assistant
Ask me anything about Chimeric Therapeutics Ltd
Financials
Annual
Quarterly
TTM

Revenue & Expenses Breakdown
Chimeric Therapeutics Ltd

Balance Sheet Decomposition
Chimeric Therapeutics Ltd

Current Assets 7.2m
Cash & Short-Term Investments 5.1m
Receivables 2m
Other Current Assets 121.6k
Non-Current Assets 11.5m
Intangibles 11.5m
Efficiency

Free Cash Flow Analysis
Chimeric Therapeutics Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Chimeric Therapeutics Ltd

Revenue
0 AUD
Operating Expenses
-17.6m AUD
Operating Income
-17.6m AUD
Other Expenses
-207.1k AUD
Net Income
-17.8m AUD
Fundamental Scores

CHM Profitability Score
Profitability Due Diligence

Chimeric Therapeutics Ltd's profitability score is 27/100. The higher the profitability score, the more profitable the company is.

27/100
Profitability
Score

Chimeric Therapeutics Ltd's profitability score is 27/100. The higher the profitability score, the more profitable the company is.

CHM Solvency Score
Solvency Due Diligence

Chimeric Therapeutics Ltd's solvency score is 46/100. The higher the solvency score, the more solvent the company is.

Low D/E
Negative Net Debt
Long-Term Solvency
Short-Term Solvency
46/100
Solvency
Score

Chimeric Therapeutics Ltd's solvency score is 46/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

CHM Price Targets Summary
Chimeric Therapeutics Ltd

There are no price targets for CHM.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Dividends

Chimeric Therapeutics Ltd
does not pay dividends
Shareholder Yield

Current shareholder yield for CHM is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

CHM Insider Trading
Buy and sell transactions by insiders

What is the Intrinsic Value of one CHM stock?

The intrinsic value of one CHM stock under the Base Case scenario is 0.01 AUD.

Is CHM stock undervalued or overvalued?

Compared to the current market price of 0.005 AUD, Chimeric Therapeutics Ltd is Undervalued by 51%.

Back to Top